Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dna X (SONM) Raw Materials (2018 - 2025)

Dna X's Raw Materials history spans 8 years, with the latest figure at $8.1 million for Q3 2025.

  • Quarterly results put Raw Materials at $8.1 million for Q3 2025, up 23.51% from a year ago — trailing twelve months through Sep 2025 was $8.1 million (up 23.51% YoY), and the annual figure for FY2024 was $5.6 million, up 645.41%.
  • Raw Materials for Q3 2025 was $8.1 million at Dna X, up from $6.3 million in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $8.1 million in Q3 2025 to a low of $3000.0 in Q2 2023.
  • The 5-year median for Raw Materials is $2.2 million (2021), against an average of $2.6 million.
  • The sharpest move saw Raw Materials crashed 99.62% in 2023, then skyrocketed 77900.0% in 2024.
  • Year by year, Raw Materials stood at $2.0 million in 2021, then plummeted by 99.3% to $14000.0 in 2022, then soared by 5264.29% to $751000.0 in 2023, then surged by 645.41% to $5.6 million in 2024, then skyrocketed by 44.34% to $8.1 million in 2025.
  • According to Business Quant data, Raw Materials over the past three periods came in at $8.1 million, $6.3 million, and $4.3 million for Q3 2025, Q2 2025, and Q1 2025 respectively.